Infant Bacterial Therapeutics AB announced earlier that the Data Monitoring Committee (DMC) performed the planned safety analysis of the study data of 1,403 babies. Company now also received results from the pre-planned futility analysis. The positive outcome of the futility analysis indicates that there is a reasonable, predefined chance that Infant Bacterial Therapeutics’ AB (IBT’s) Connection Study will achieve a significant therapeutic effect with respect to the primary endpoint, prevention of Necrotizing Enterocolitis (NEC).